{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:59:04Z","timestamp":1790416744942,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["SPE20170336816"],"award-info":[{"award-number":["SPE20170336816"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.acvd.2019.09.006","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T06:42:04Z","timestamp":1572763324000},"page":"9-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study"],"prefix":"10.1016","volume":"113","author":[{"given":"Marie","family":"Bretagne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel G.","family":"Malouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Dureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Potey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl.\u00a05","key":"10.1016\/j.acvd.2019.09.006_bib0005","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.acvd.2019.09.006_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2019.09.006_bib0020","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2019.09.006_bib0025","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2019.09.006_bib0030","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11594540-000000000-00000","article-title":"Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care","volume":"34","author":"Martin-Merino","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.acvd.2019.09.006_bib0040","first-page":"6","article-title":"Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation","volume":"9","author":"Sharma","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2019.09.006_bib0045","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2019.09.006_bib0050","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1210\/jc.2016-1877","article-title":"Complex influence of gonadotropins and sex steroid hormones on QT interval duration","volume":"101","author":"Abehsira","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.acvd.2019.09.006_bib0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pharmthera.2016.07.005","article-title":"Influence of steroid hormones on ventricular repolarization","volume":"167","author":"Salem","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.acvd.2019.09.006_bib0060","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/cvr\/cvz020","article-title":"Cardiac arrhythmia considerations of hormone cancer therapies","volume":"115","author":"Barber","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2019.09.006_bib0065","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.119.040162","article-title":"Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes","author":"Salem","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2019.09.006_bib0070","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jamacardio.2018.2251","article-title":"Association of oral contraceptives with drug-induced QT interval prolongation in healthy nonmenopausal women","volume":"3","author":"Salem","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.acvd.2019.06.008","article-title":"Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: a review and pharmacovigilance study","author":"Salem","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2019.09.006_bib0080","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1001\/jama.2011.1791","article-title":"Androgen deprivation therapy and competing risks","volume":"306","author":"Kelly","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2019.09.006_bib0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2019.09.006_bib0090","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0095","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O\u2019Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","article-title":"Hypogonadism as a reversible cause of torsades de pointes in men","volume":"138","author":"Salem","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2019.09.006_bib0105","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1136\/heartjnl-2017-312934","article-title":"Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors","volume":"104","author":"Grouthier","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2019.09.006_bib0110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR Database System: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Info J"},{"key":"10.1016\/j.acvd.2019.09.006_bib0115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","article-title":"Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions","volume":"26","author":"van Puijenbroek","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.acvd.2019.09.006_bib0120","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/eurheartj\/ehi092","article-title":"Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death","volume":"26","author":"De Bruin","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2019.09.006_bib0125","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.acvd.2019.09.006_bib0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.acvd.2019.09.006_bib0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2265.2006.02715.x","article-title":"Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study","volume":"66","author":"Chung","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.acvd.2019.09.006_bib0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCHEARTFAILURE.111.965632","article-title":"Testosterone supplementation in heart failure: a meta-analysis","volume":"5","author":"Toma","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.acvd.2019.09.006_bib0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.echo.2017.10.017","article-title":"Complex association of sex hormones on left ventricular systolic function: insight into sexual dimorphism","volume":"31","author":"Salem","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.acvd.2019.09.006_bib0150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2019.09.006_bib0155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2016.02.013","article-title":"Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials","volume":"101","author":"Roviello","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acvd.2019.09.006_bib0165","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0175","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2019.09.006_bib0180","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bjc.2017.280","article-title":"Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study","volume":"117","author":"Haque","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.acvd.2019.09.006_bib0185","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.acvd.2019.09.006_bib0190","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.tranon.2016.08.001","article-title":"Association of biomarkers with serious cardiac adverse events during abiraterone acetate treatment in castration resistant prostate cancer","volume":"9","author":"Campora","year":"2016","journal-title":"Transl Oncol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejca.2016.11.027","article-title":"Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients","volume":"72","author":"Carton","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acvd.2019.09.006_bib0200","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.acvd.2019.09.006_bib0205","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ctrv.2013.03.003","article-title":"Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone","volume":"39","author":"Pia","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.acvd.2019.09.006_bib0210","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/CIRCULATIONAHA.109.915215","article-title":"Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via \u201cnongenomic effects\u201d","volume":"122","author":"Mohammed","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2019.09.006_bib0215","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/eurheartj\/ehr292","article-title":"Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction","volume":"33","author":"Edelmann","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2019.09.006_bib0220","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2019.09.006_bib0225","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2019.09.006_bib0230","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1016\/j.ijcard.2013.08.022","article-title":"Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural\/electrical remodeling","volume":"168","author":"Mayyas","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0235","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jelectrocard.2015.12.012","article-title":"A porcine model of early atrial fibrillation using a custom-built, radio transmission-controlled pacemaker","volume":"49","author":"Schwarzl","year":"2016","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0240","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1159\/000178483","article-title":"Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat","volume":"29","author":"Lammers","year":"2012","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.acvd.2019.09.006_bib0245","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1530\/eje.0.1510397","article-title":"Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties","volume":"151","author":"Grossmann","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.acvd.2019.09.006_bib0250","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0022-4731(88)90295-6","article-title":"Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture","volume":"31","author":"Luthy","year":"1988","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.acvd.2019.09.006_bib0255","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salame","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.acvd.2019.09.006_bib0260","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.2016.21043","article-title":"Testosterone treatment and coronary artery plaque volume in older men with low testosterone","volume":"317","author":"Budoff","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.acvd.2019.09.006_bib0265","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187521361930172X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187521361930172X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:45:31Z","timestamp":1761745531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187521361930172X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S187521361930172X"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2019.09.006","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2019.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}